Published in J Pharmacol Exp Ther on March 19, 2008
International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂. Pharmacol Rev (2010) 4.31
Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol (2011) 1.81
Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas. Glia (2010) 1.70
The transient receptor potential channel TRPA1: from gene to pathophysiology. Pflugers Arch (2012) 1.63
Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol (2011) 1.53
Nitrooleic acid, an endogenous product of nitrative stress, activates nociceptive sensory nerves via the direct activation of TRPA1. Mol Pharmacol (2009) 1.33
Transient receptor potential (TRP) channels: a clinical perspective. Br J Pharmacol (2014) 1.25
Molecular architecture and subunit organization of TRPA1 ion channel revealed by electron microscopy. J Biol Chem (2011) 1.17
Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Philos Trans R Soc Lond B Biol Sci (2012) 1.15
Modulation of L-α-lysophosphatidylinositol/GPR55 mitogen-activated protein kinase (MAPK) signaling by cannabinoids. J Biol Chem (2011) 1.11
Role of ionotropic cannabinoid receptors in peripheral antinociception and antihyperalgesia. Trends Pharmacol Sci (2008) 1.01
Alcohol-binding sites in distinct brain proteins: the quest for atomic level resolution. Alcohol Clin Exp Res (2011) 0.99
Non-psychoactive cannabinoids modulate the descending pathway of antinociception in anaesthetized rats through several mechanisms of action. Br J Pharmacol (2011) 0.96
The nonpsychoactive cannabinoid cannabidiol inhibits 5-hydroxytryptamine3A receptor-mediated currents in Xenopus laevis oocytes. J Pharmacol Exp Ther (2010) 0.96
The therapeutic potential of novel cannabinoid receptors. Pharmacol Ther (2009) 0.95
TRPM8 activation attenuates inflammatory responses in mouse models of colitis. Proc Natl Acad Sci U S A (2013) 0.94
Inhibitory effect of cannabichromene, a major non-psychotropic cannabinoid extracted from Cannabis sativa, on inflammation-induced hypermotility in mice. Br J Pharmacol (2012) 0.93
Evidence that the plant cannabinoid cannabigerol is a highly potent alpha2-adrenoceptor agonist and moderately potent 5HT1A receptor antagonist. Br J Pharmacol (2009) 0.93
A structural view of ligand-dependent activation in thermoTRP channels. Front Physiol (2014) 0.92
The endocannabinoid system in prostate cancer. Nat Rev Urol (2011) 0.92
Cannabinoids and Epilepsy. Neurotherapeutics (2015) 0.91
Mode of action of cannabinoids on nociceptive nerve endings. Exp Brain Res (2009) 0.90
Modulation of mouse gastrointestinal motility by allyl isothiocyanate, a constituent of cruciferous vegetables (Brassicaceae): evidence for TRPA1-independent effects. Br J Pharmacol (2012) 0.90
Non-THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo: pro-apoptotic effects and underlying mechanisms. Br J Pharmacol (2013) 0.89
Interaction between non-psychotropic cannabinoids in marihuana: effect of cannabigerol (CBG) on the anti-nausea or anti-emetic effects of cannabidiol (CBD) in rats and shrews. Psychopharmacology (Berl) (2011) 0.88
Modulation of thermoreceptor TRPM8 by cooling compounds. ACS Chem Neurosci (2012) 0.88
The cannabinoid TRPA1 agonist cannabichromene inhibits nitric oxide production in macrophages and ameliorates murine colitis. Br J Pharmacol (2013) 0.88
Transient receptor potential channels as targets for phytochemicals. ACS Chem Neurosci (2014) 0.88
Cannabidiolic acid prevents vomiting in Suncus murinus and nausea-induced behaviour in rats by enhancing 5-HT1A receptor activation. Br J Pharmacol (2013) 0.85
Update on the role of cannabinoid receptors after ischemic stroke. Mediators Inflamm (2012) 0.85
Effect of low doses of cannabidiolic acid and ondansetron on LiCl-induced conditioned gaping (a model of nausea-induced behaviour) in rats. Br J Pharmacol (2013) 0.83
Desensitization of transient receptor potential ankyrin 1 (TRPA1) by the TRP vanilloid 1-selective cannabinoid arachidonoyl-2 chloroethanolamine. Mol Pharmacol (2011) 0.83
Trafficking of ThermoTRP Channels. Membranes (Basel) (2014) 0.83
TRP channel cannabinoid receptors in skin sensation, homeostasis, and inflammation. ACS Chem Neurosci (2014) 0.82
TRPA1 mediates the hypothermic action of acetaminophen. Sci Rep (2015) 0.80
Targeting TRP channels for chronic cough: from bench to bedside. Naunyn Schmiedebergs Arch Pharmacol (2015) 0.80
The Endocannabinoid System and its Modulation by Phytocannabinoids. Neurotherapeutics (2015) 0.80
Molecular Targets of Cannabidiol in Neurological Disorders. Neurotherapeutics (2015) 0.79
Nociceptive TRP Channels: Sensory Detectors and Transducers in Multiple Pain Pathologies. Pharmaceuticals (Basel) (2016) 0.78
A putative 'pre-nervous' endocannabinoid system in early echinoderm development. Dev Neurosci (2009) 0.78
Cannabidiol inhibits synaptic transmission in rat hippocampal cultures and slices via multiple receptor pathways. Br J Pharmacol (2011) 0.77
Leucettamols, bifunctionalized marine sphingoids, act as modulators of TRPA1 and TRPM8 channels. Mar Drugs (2012) 0.77
Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes. J Clin Invest (2014) 0.77
Regulatory effects of anandamide on intracellular Ca(2+) concentration increase in trigeminal ganglion neurons. Neural Regen Res (2014) 0.77
Cannabis constituents modulate δ9-tetrahydrocannabinol-induced hyperphagia in rats. Psychopharmacology (Berl) (2010) 0.76
Molecular Targets of the Phytocannabinoids: A Complex Picture. Prog Chem Org Nat Prod (2017) 0.75
Differential regulation of calcium signalling pathways by components of Piper methysticum ('Awa). Phytother Res (2015) 0.75
Molecular mechanisms involved in the antitumor activity of cannabinoids on gliomas: role for oxidative stress. Cancers (Basel) (2010) 0.75
SuperPain--a resource on pain-relieving compounds targeting ion channels. Nucleic Acids Res (2013) 0.75
Cannabinoid 1 receptor knockout mice display cold allodynia, but enhanced recovery from spared-nerve injury-induced mechanical hypersensitivity. Mol Pain (2016) 0.75
Epigenetic control of skin differentiation genes by phytocannabinoids. Br J Pharmacol (2013) 0.75
The endogenous cannabinoid system controls extinction of aversive memories. Nature (2002) 7.19
CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science (2003) 5.22
Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science (2005) 5.12
Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J Cell Biol (2003) 3.60
An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc Natl Acad Sci U S A (2002) 3.16
Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab (2006) 2.72
Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol (2002) 2.54
Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats. Hepatology (2007) 2.48
Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci (2009) 2.32
Circulating and hepatic endocannabinoids and endocannabinoid-related molecules in patients with cirrhosis. Liver Int (2009) 2.27
Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia (2014) 1.97
Possible endocannabinoid control of colorectal cancer growth. Gastroenterology (2003) 1.89
Endovanilloids. Putative endogenous ligands of transient receptor potential vanilloid 1 channels. Eur J Biochem (2004) 1.87
The endocannabinoid system: a general view and latest additions. Br J Pharmacol (2004) 1.77
Endocannabinoids and the control of energy balance. Trends Endocrinol Metab (2006) 1.74
Attenuation of allergic contact dermatitis through the endocannabinoid system. Science (2007) 1.70
The 'headache tree' via umbellulone and TRPA1 activates the trigeminovascular system. Brain (2011) 1.70
The endocannabinoid system in energy homeostasis and the etiopathology of metabolic disorders. Cell Metab (2013) 1.67
Overactivity of the intestinal endocannabinoid system in celiac disease and in methotrexate-treated rats. J Mol Med (Berl) (2007) 1.65
Biochemistry and pharmacology of endovanilloids. Pharmacol Ther (2007) 1.64
Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J Pharmacol Exp Ther (2006) 1.61
An endogenous cannabinoid tone attenuates cholera toxin-induced fluid accumulation in mice. Gastroenterology (2003) 1.60
Elevation of endocannabinoid levels in the ventrolateral periaqueductal grey through inhibition of fatty acid amide hydrolase affects descending nociceptive pathways via both cannabinoid receptor type 1 and transient receptor potential vanilloid type-1 receptors. J Pharmacol Exp Ther (2005) 1.56
Peripheral endocannabinoid dysregulation in obesity: relation to intestinal motility and energy processing induced by food deprivation and re-feeding. Br J Pharmacol (2009) 1.55
Changes in spinal and supraspinal endocannabinoid levels in neuropathic rats. Neuropharmacology (2006) 1.54
Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol (2011) 1.53
Prefrontal cortex stimulation induces 2-arachidonoyl-glycerol-mediated suppression of excitation in dopamine neurons. J Neurosci (2004) 1.52
Endocannabinoid dysregulation in the pancreas and adipose tissue of mice fed with a high-fat diet. Obesity (Silver Spring) (2008) 1.51
Anandamide acts as an intracellular messenger amplifying Ca2+ influx via TRPV1 channels. EMBO J (2005) 1.48
N-oleoyldopamine, a novel endogenous capsaicin-like lipid that produces hyperalgesia. J Biol Chem (2003) 1.48
Endocannabinoid signaling controls pyramidal cell specification and long-range axon patterning. Proc Natl Acad Sci U S A (2008) 1.47
Endocannabinoids as physiological regulators of colonic propulsion in mice. Gastroenterology (2002) 1.41
Presynaptic facilitation of glutamatergic synapses to dopaminergic neurons of the rat substantia nigra by endogenous stimulation of vanilloid receptors. J Neurosci (2003) 1.41
Endocannabinoids may mediate the ability of (n-3) fatty acids to reduce ectopic fat and inflammatory mediators in obese Zucker rats. J Nutr (2009) 1.39
Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine. Brain Res (2002) 1.38
Cannabinoid CB1 receptor mediates fear extinction via habituation-like processes. J Neurosci (2006) 1.37
Impaired nociception and inflammatory pain sensation in mice lacking the prokineticin receptor PKR1: focus on interaction between PKR1 and the capsaicin receptor TRPV1 in pain behavior. J Neurosci (2006) 1.37
An introduction to the endocannabinoid system: from the early to the latest concepts. Best Pract Res Clin Endocrinol Metab (2009) 1.36
Up-regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation. FASEB J (2006) 1.36
FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels. Curr Opin Investig Drugs (2010) 1.34
Blood levels of the endocannabinoid anandamide are increased in anorexia nervosa and in binge-eating disorder, but not in bulimia nervosa. Neuropsychopharmacology (2005) 1.33
Development of the first potent and specific inhibitors of endocannabinoid biosynthesis. Biochim Biophys Acta (2006) 1.31
Depolarization-induced retrograde synaptic inhibition in the mouse cerebellar cortex is mediated by 2-arachidonoylglycerol. J Physiol (2006) 1.30
The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders. Eur J Pharmacol (2003) 1.30
Dysregulation of peripheral endocannabinoid levels in hyperglycemia and obesity: Effect of high fat diets. Mol Cell Endocrinol (2008) 1.30
Endocannabinoid signalling in the blood of patients with schizophrenia. Lipids Health Dis (2003) 1.29
Novel selective and metabolically stable inhibitors of anandamide cellular uptake. Biochem Pharmacol (2003) 1.29
An NMR spectroscopic method to identify and classify thiol-trapping agents: revival of Michael acceptors for drug discovery? Angew Chem Int Ed Engl (2011) 1.26
The endocannabinoid signalling system: biochemical aspects. Pharmacol Biochem Behav (2005) 1.25
Mechanisms of the anti-obesity effects of oxytocin in diet-induced obese rats. PLoS One (2011) 1.24
Acute neuronal injury, excitotoxicity, and the endocannabinoid system. Mol Neurobiol (2002) 1.24
Selective inhibition of anandamide cellular uptake versus enzymatic hydrolysis--a difficult issue to handle. Eur J Pharmacol (2004) 1.24
Presence and regulation of the endocannabinoid system in human dendritic cells. Eur J Biochem (2002) 1.22
Anxiolytic effects in mice of a dual blocker of fatty acid amide hydrolase and transient receptor potential vanilloid type-1 channels. Neuropsychopharmacology (2008) 1.21
Anandamide inhibits adhesion and migration of breast cancer cells. Exp Cell Res (2005) 1.21
Cannabinoid receptor 1 blockade ameliorates albuminuria in experimental diabetic nephropathy. Diabetes (2010) 1.21
Evolutionary origins of the endocannabinoid system. Gene (2006) 1.21
TRPV1 receptors in the central nervous system: potential for previously unforeseen therapeutic applications. Curr Pharm Des (2008) 1.21
Tonic endovanilloid facilitation of glutamate release in brainstem descending antinociceptive pathways. J Neurosci (2007) 1.20
N-palmitoyl-ethanolamine: Biochemistry and new therapeutic opportunities. Biochimie (2010) 1.19
Cannabinoid receptors and endocannabinoids: role in neuroinflammatory and neurodegenerative disorders. CNS Neurol Disord Drug Targets (2010) 1.19
Endocannabinoids link feeding state and auditory perception-related gene expression. J Neurosci (2004) 1.18
TRPV1 channels control synaptic plasticity in the developing superior colliculus. J Physiol (2009) 1.17
Tetrahydrolipstatin analogues as modulators of endocannabinoid 2-arachidonoylglycerol metabolism. J Med Chem (2008) 1.16
Further evidence for the existence of a specific process for the membrane transport of anandamide. Biochem J (2004) 1.16
Role of cannabinoid CB1 receptors and tumor necrosis factor-alpha in the gut and systemic anti-inflammatory activity of SR 141716 (rimonabant) in rodents. Br J Pharmacol (2003) 1.15
Inhibitory effects of cannabinoid CB1 receptor stimulation on tumor growth and metastatic spreading: actions on signals involved in angiogenesis and metastasis. FASEB J (2003) 1.15
Neural precursor cells induce cell death of high-grade astrocytomas through stimulation of TRPV1. Nat Med (2012) 1.15
Regulation of transient receptor potential channels of melastatin type 8 (TRPM8): effect of cAMP, cannabinoid CB(1) receptors and endovanilloids. Exp Cell Res (2007) 1.14
N-arachidonoyl-dopamine tunes synaptic transmission onto dopaminergic neurons by activating both cannabinoid and vanilloid receptors. Neuropsychopharmacology (2006) 1.14
Functional expression of AMPA receptors on central terminals of rat dorsal root ganglion neurons and presynaptic inhibition of glutamate release. Neuron (2002) 1.13
Fatty acid amide hydrolase controls mouse intestinal motility in vivo. Gastroenterology (2005) 1.12
Are cannabidiol and Δ(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. Br J Pharmacol (2015) 1.12
Identification of endocannabinoids and related compounds in human fat cells. Obesity (Silver Spring) (2007) 1.12
Low fatty acid amide hydrolase and high anandamide levels are associated with failure to achieve an ongoing pregnancy after IVF and embryo transfer. Mol Hum Reprod (2002) 1.12
DAG lipase involvement in depolarization-induced suppression of inhibition: does endocannabinoid biosynthesis always meet the demand? Neuroscientist (2010) 1.12
Finding of endocannabinoids in human eye tissues: implications for glaucoma. Biochem Biophys Res Commun (2005) 1.11
Fatty acid amide hydrolase, an enzyme with many bioactive substrates. Possible therapeutic implications. Curr Pharm Des (2002) 1.10
The endocannabinoid system is modulated in response to spinal cord injury in rats. Neurobiol Dis (2008) 1.10
Cannabinoid receptors and their role in neuroprotection. Neuromolecular Med (2005) 1.09
Non-CB1, non-CB2 receptors for endocannabinoids, plant cannabinoids, and synthetic cannabimimetics: focus on G-protein-coupled receptors and transient receptor potential channels. J Neuroimmune Pharmacol (2009) 1.09
Targeting the endocannabinoid system in cancer therapy: a call for further research. Nat Med (2002) 1.09
Differential alterations of the concentrations of endocannabinoids and related lipids in the subcutaneous adipose tissue of obese diabetic patients. Lipids Health Dis (2010) 1.09
Protective role of cannabinoid receptor type 2 in a mouse model of diabetic nephropathy. Diabetes (2011) 1.08
The endocannabinoid system and pivotal role of the CB2 receptor in mouse spermatogenesis. Proc Natl Acad Sci U S A (2009) 1.08
Increased endocannabinoid levels reduce the development of precancerous lesions in the mouse colon. J Mol Med (Berl) (2007) 1.07
Effect of dietary fat on endocannabinoids and related mediators: consequences on energy homeostasis, inflammation and mood. Mol Nutr Food Res (2010) 1.07
The endocannabinoid system and the molecular basis of paralytic ileus in mice. FASEB J (2002) 1.06
Development of a potent inhibitor of 2-arachidonoylglycerol hydrolysis with antinociceptive activity in vivo. Biochim Biophys Acta (2008) 1.06
Involvement of the cannabimimetic compound, N-palmitoyl-ethanolamine, in inflammatory and neuropathic conditions: review of the available pre-clinical data, and first human studies. Neuropharmacology (2005) 1.06
A structure-activity relationship study on N-arachidonoyl-amino acids as possible endogenous inhibitors of fatty acid amide hydrolase. Biochem Biophys Res Commun (2004) 1.05
Noladin ether, a putative novel endocannabinoid: inactivation mechanisms and a sensitive method for its quantification in rat tissues. FEBS Lett (2002) 1.05